<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="3181">Bromocriptine</z:chebi> is an <z:chebi fb="0" ids="23943">ergot alkaloid</z:chebi> <z:chebi fb="40" ids="18243">dopamine</z:chebi> D(2) receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> that has been used extensively in the past to treat <z:hpo ids='HP_0000870'>hyperprolactinaemia</z:hpo>, <z:hpo ids='HP_0100829'>galactorrhoea</z:hpo> and <z:hpo ids='HP_0001300'>Parkinsonism</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>It is known that hypothalamic hypodopaminergic states and disturbed circadian rhythm are associated with the development of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp> in animals and humans </plain></SENT>
<SENT sid="2" pm="."><plain>When administered in the early morning at the start of the light phase, a new quick release (QR) formulation of <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> appears to act centrally to reset circadian rhythms of hypothalamic <z:chebi fb="40" ids="18243">dopamine</z:chebi> and <z:chebi fb="19" ids="28790">serotonin</z:chebi> and improve <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and other <z:mp ids='MP_0005266'>metabolic abnormalities</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Phase II and III clinical studies show that QR-<z:chebi fb="0" ids="3181">bromocriptine</z:chebi> lowers glycated <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> by 0.6-1.2% (7-13 mmol/mol) either as monotherapy or in combination with other antidiabetes medications </plain></SENT>
<SENT sid="4" pm="."><plain>Apart from <z:hpo ids='HP_0002018'>nausea</z:hpo>, the drug is well tolerated </plain></SENT>
<SENT sid="5" pm="."><plain>The doses used to treat <z:mp ids='MP_0002055'>diabetes</z:mp> (up to 4.8 mg daily) are much lower than those used to treat <z:e sem="disease" ids="C0030567" disease_type="Disease or Syndrome" abbrv="PD">Parkinson's disease</z:e> and have not been associated with <z:hpo ids='HP_0005200'>retroperitoneal fibrosis</z:hpo> or heart valve abnormalities </plain></SENT>
<SENT sid="6" pm="."><plain>QR-<z:chebi fb="0" ids="3181">bromocriptine</z:chebi> (Cyclosetâ„¢) has recently been approved in the USA for the treatment of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) </plain></SENT>
<SENT sid="7" pm="."><plain>Thus, a QR formulation of <z:chebi fb="0" ids="3181">bromocriptine</z:chebi> timed for peak delivery in the early morning may provide a novel neurally mediated approach to the control of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> in T2DM </plain></SENT>
</text></document>